This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
A long-term phase 4 study to evaluate the risk of idiosyncratic hepatotoxicity associated with pexidartinib treatment
Poster
T-DXd
AACR 2025 | April 25-29, 2025
An open-label, multicenter, phase 2 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
An open-label, multicenter, phase 2 study of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 2
Mini-Oral
Dato-DXd
ASCO Genitourinary Cancers Symposium | February 13-15, 2025
Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPION PanTumor01 study
Poster
Valemetostat
ASCPT 2025 | May 28-31, 2025
Effect of valemetostat on the pharmacokinetics of midazolam and digoxin (CYP3A and P-gp substrates): A phase 1 drug–drug interaction study in patients with refractory or relapsed non-hodgkin lymphoma
Poster
I-DXd
SITC 2024 | November 6-10, 2024
Evaluation of immunomodulatory effects of ifinatamab deruxtecan (I-DXd) in the IDeate-PanTumor01 phase 1/2 study in patients with advanced solid tumors
Oral
Other/Multi
JSMO 2025 | March 6-8, 2025
Expression of tumor-associated mucin 1 in bladder and upper urinary tract cancers
Poster
Pexidartinib
CTOS 2024 | November 13- 16, 2024
Health-related quality of life from a phase 4 global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib
Poster
HER3-DXd
ESMO 2024 | September 13-17, 2024
HERTHENA-PanTumor01: A global, phase 2 trial of HER3-DXd in metastatic solid tumors
Poster
I-DXd
ASCO 2025 | May 30-June 3,2025
IDeate-PanTumor02: A phase 1b/2 study to evaluate the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with recurrent or metastatic solid tumors
Pages:
1 2